ISSUES RELATED TO HPV VACCINE ACCEPTANCE: LESSONS FROM THE DANISH HPV VACCINE EXPERIENCE

Similar documents
Workshop 5: HPV vaccination programs in Europe, lessons learnt and the way forward.

HPV, Cancer and the Vaccination Programme

The Danish childhood vaccination program SUMMARY IN ENGLISH

Questions and answers about HPV. Facts about the virus and the vaccine

Global Advisory Committee on Vaccine Safety (GACVS) Report from the June 2017 meeting

Measles and rubella monitoring January 2015

Human Papillomavirus Immunisation Programme. Background

Examples of Nordic collaborations: benefits and challenges

HPV vaccine the global perspective

The effects of immunisation on infection and Disease

Lessons Learned from Adverse Events and Assessment of Causal Relationships. Neal A. Halsey Johns Hopkins University

Planning an effective HPV vaccination launch: The key indicators for success Joakim Dillner

Vaccine Hesitancy: an international perspective

Measuring and monitoring vaccine confidence

EUVAC.NET A surveillance network for vaccine-preventable diseases

Assessing the Safety of Vaccines at the FDA: Pre- and Post-Licensure Evaluation

Media monitoring: Experience of outbreak monitoring at ECDC to monitor vaccine safety potential crisis- A pilot using MediSYS

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

What You Need to Know about Vaccine Safety

Vaccination schedules in Denmark

Facts about HPV vaccine

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010

Cervical Cancer Prevention in Japan: Troubling Times

HPV Vaccine Safety & Effectiveness

The National Immunisation Schedule. Dr Brenda Corcoran.

DANISH PHARMACOVIGILANCE UPDATE

The schedule for childhood vaccination is:(web link to NHS Childhood Immunisation Schedule for 2008

Adverse Events Following Immunisation. Kevin Connolly Limerick, Sept. 22, 2016

Nationwide enrichment of biological sample data with data from health registers the Danish Biobank Register search system

Vaccine hesitancy in the EU: state of play and impact on vaccination programmes

HPV Vaccination: A Missed Opportunity for Cancer Prevention. New Developments in Objectives for today s talk

The challenge of vaccine hesitancy in the European Union

CDC s Public Health Research on Autism

The HPV vaccination programme in Flanders. Geert Top MD Infectious disease control and vaccination

Investigation of the association between narcolepsy and vaccination with Pandemrix

The Future of Cervical Cancer Prevention

Annual measles notifications & vaccine coverage England and Wales

Global and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office.

in the United States during the period ACIP to routinely receive HPV vaccination.

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

Harnessing the power of vaccines using the public and private sector: A 21 st century model for international development

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

Impact and effectiveness of national immunisation programmes. David Green, Nurse Consultant, Immunisations Public Health England

Adult Immunizations. Business Health Care Group (BHCG) April 25, Cathy Edwards. Immunization Program Advisor

Vaccine Safety: Its everyone s business! PHO Rounds: Nov 19, 2013

27 th Nordic Medical History Congress

Thursday, 21 September Vaccine Safety HPV. Helen Petousis-Harris, PhD National Immunisation Workshop Sept 2017

We have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci

Measles outbreak in Greater Manchester, England, October 2012 to September 2013: epidemiology and control

Understanding Adverse Events

UICC HPV and CERVICAL CANCER CURRICULUM. UICC HPV and Cervical Cancer Curriculum Chapter 5. Application of HPV vaccines Prof. Suzanne Garland MD

Methodologies for vaccine safety surveillance. Nick Andrews, Statistics Unit Public Health England October 2015

Evaluating Effective Messaging for HPV Vaccination Promotion. Jaleen Sims, MPH, MSIV Central Mississippi Health Service, Inc Jackson, MS

The national human papillomavirus (HPV) vaccination programme - the move to two-dose schedule

National Cancer Update. Stephen Parsons Director

Risk and Uncertainty. The Precautionary Principle: Immunisation safety: risks, benefits and precautions.

Neurotoxic Effects of Mercury in Dental Nurses

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

NHS public health functions agreement Service specification No.11 Human papillomavirus (HPV) programme

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

The HPV Vaccination Programme Early intervention in cancer prevention Northern Ireland

Vaccine Hesitancy- Current Issues and Controversies including HPV vaccine. Dr Brenda Corcoran National Immunisation Office

Vaccine Confidence Current Issues and Controversies including HPV vaccine. Dr Brenda Corcoran National Immunisation Office

Your guide to the HPV vaccine

Expanded Eligibility for Human Papillomavirus (HPV) Vaccination for Select Male Populations Q&A Document August 2015

Recommended vaccines in the United States. Maki Kano, MD September 23, 2017 Apple Time

Influenza vaccine effectiveness assessment in the UK. Nick Andrews, Statistics Unit, Health Protection Agency

OBESITY AMONG DANISH SEAFARERS

HPV vaccination How to promote women s health and prevent cancer with good screening strategies, hosted by NFOG

Serious Adverse Event (SAE) Form Clinical Trials

Turning Mapping into Action

Table Of Content. Outputs... 7

Beating cervical cancer

Measles Elimination Dr. Suzanne Cotter 4 th National Immunisation Conference 2007

Serious Adverse Event (SAE) Form Clinical Trials

Bias and confounding. Mads Kamper-Jørgensen, associate professor, Section of Social Medicine

Pharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.

EUROPEAN IMMUNIZATION WEEK APRIL Communications package

Table Of Content. Invasive Bacterial Infections Surveillance in the European Union... 2 Summary... 3 Coordinator, Leader contact and partners...

Samir K Saha, Ph.D Child Health Research Foundation Dhaka Shishu Hospital Dhaka, Bangladesh

Increasing HPV Vaccination Rates in NYS. Jim Kirkwood NYSDOH, Bureau of Immunization

HPV Immunisation Statistics Scotland

European Medicines Agency decision

Eradicating cervical cancer. Our role in making it a reality

Paper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2013:

The power of partnership: the GAVI Alliance Board

Vaccination uptake by vaccine hesitant parents attending a Specialist Immunisation Clinic in Australia.

Monthly measles and rubella monitoring report

Analysis of 3-dose oral/inactivated poliovirus vaccine (OPV3/IPV3) immunization coverage

How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries?

Update on public hearing

The HPV immunisation programme was introduced in 2008 at which time the vaccine used was Cervarix

Human Papillomavirus Vaccination Programme in Malaysia

Adverse Event Reporting Programme for Veterinary Medicines

Progress in improving cancer services and outcomes in England. Report. Department of Health, NHS England and Public Health England

Director of Public Health Board Paper No. 13/13

ORAL ACTION CANCER. A Plan for

Transcription:

ISSUES RELATED TO HPV VACCINE ACCEPTANCE: LESSONS FROM THE DANISH HPV VACCINE EXPERIENCE Palle Valentiner-Branth, MD, PhD Head of VPD group Department of Infectious Disease Epidemiology & Prevention Statens Serum Institut, Denmark BUILDING TRUST, MANAGING RISK: VACCINE CONFIDENCE AND HUMAN PAPILLOMAVIRUS VACCINATION 7-8 June 2017 - LSHTM, London

IMPLEMENTATION OF HPV PROGRAMMES

HPV VACCINE UPTAKE OF FIRST DOSE BY BIRTH COHORT Source: www.ssi.dk/data

TIMELINE Summer 2013: Report of seven cases of POTS to Danish Medicines Agency (DMA), A signal is raised with EMA December 2014: EMA concludes that a causal relationship between Gardasil and POTS could neither be confirmed nor rejected. February 2015: Case series consisting of 53 persons referred to the syncope unit in Copenhagen was published March 2015: participates in The vaccinated girls a TV documentary. Recommends a suspension of the programme and notes that especially physically active girls are at risk. June 2015: Clinics in the five Danish Regions where girls who suspects HPV side effects can be referred to are established Dan Med J 2015;62(4):A5064

Reporting of adverse events: Stimulated by the programme The Vaccinated Girls broadcasted 26 March 2015, by TV2 Features interviews with families and vaccinated girls with medically unexplained symptoms.

ADVERSE EVENT REPORTS RECEIVED PER YEAR IN DK An adverse event report is received for 0,4% of the vaccinated (4 per 1000) In 2016, only 17 non-serious reports related to vaccinations done in 2016 were received. 2009 2010 2011 2012 2013 2014 2015 2016 Total Total reports Serious reports * 288 66 43 96 511 224 822 307 2326 25 5 6 18 177 91 475 182 1005 * Seriousness defined according to ICH and EMA criteria: Results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. 16.06.2017

TIMELINE CONTINUED July 2015: DMA makes a referral to EMA/PRAC regarding POTS and CRPS November 2015: EMA concludes that these conditions are not more common in vaccinated compared to unvaccinated. Head of Parlament health committee response to the EMA-report: The doctors in the committee have connections to the industry and can t be trusted. The programme should be stopped. She believes that the HPV vaccines causes the reported adverse reactions. December 2015: Public hearing in the Danish Parlament. June 2016: 1 million Euro for research projects investigating the alleged side effects: More than half of the these funds were awarded to the syncope unit. September 2016

STUDIES PRIOR AND POST HPV INTRODUCTION Baseline for immune mediated adverse events and cohort study among vaccinated and unvaccinated

TRENDS OF HPV VACCINE UPTAKE OF FIRST DOSE BY BIRTH COHORT IN THE NORDIC COUNTRIES BY END 2016

THE DANISH SIGNAL : QUESTIONS AND CONCERNS The signal consisted mainly of medically unexplained physical symptoms in vaccinated girls No evidence from analytical studies - No studies have demonstrated an increased risk among vaccinated girls compared with unvaccinated Difficult to analyse in epidemiological studies - CFS/ME and POTS are ill-defined conditions Reporting has been stimulated by media attention, social media and infostorms Data from passive adverse events surveillance are biased Females with suspected adverse reactions has symptoms and a health-care seeking pattern that is different from a matched population. Pre-vaccination morbidity should be taken into account in the evaluation of vaccine safety signals Next steps planned: A large part of the target population, i.e. mothers of the 12 year old girls are hesitant regarding HPV vaccination. They are affected by histories of adverse events and news media. Many gets all information from social media where the authorities are not very active Information campaign led by Danish Health Authority is now launched

Duration two years, facebook, youtube, short movies, homepage, information material to GP s. HPV vaccination is supported by a broad group of health persons and patient groups

THANK YOU TO SWEDEN (TIIA LEPP) NORWAY (LILL TROGSTAD) FINLAND (HANNA NOHYNEK) ICELAND (THOROLFUR GUDNASSON)